Orientation and Mobility
Marshall Flax, MS, is a Certified Orientation and Mobility Specialist with over 30 years of experience in the field. He has provided instruction to children and adults throughout Wisconsin and Northern Illinois in neighborhood settings, at work sites, and on campuses. Marshall has worked with a wide range of clients including those with other disabilities.
“I provide one-on-one O&M instruction in ‘real life’ settings that are relevant to the client. Goals may include acquiring skills to travel safely and efficiently using a white cane. For clients who already possess adequate travel skills, I can provide orientation to routes to and from school or work, or to destinations within a school or work campus. Lessons are constructed to help the client meet his or her goals. The entity that contracts with Fork in the Road (e.g. vocational rehabilitation, campus disability services, school) will receive a written report on the services provided to their client or student.”Read more in this article about Marshall Flax
Marshall’s professional experience includes:
- Recently taught at UW-Platteville.
“Anatomy and Physiology of the Eye and Implications for Low Vision” a graduate program course for teachers - Masters degree from University of Wisconsin-Madison and over 30 years experience in O&M
- O&M Internship/practicum supervisor for:
- Western Michigan University
- University of Arkansas-Little Rock
- University of Pittsburgh
- Editorial Advisory Board: Journal of Visual Impairment & Blindness
- Adjunct faculty: Silver Lake College, Manitowoc, WI, Division of Graduate Studies: Special Education Studies
- Member, Advisory Board, McPherson Eye Research Institute, University of Wisconsin-Madison
- Orientation and mobility consultant to:
- Wicab: maker of the BrainPort vision device
- Second Sight Medical Products: maker of the Argus II retinal chip
- Salus University: “A Safety and Efficacy Study in Subjects with Leber’s Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE)”. Center for Cellular and Molecular Therapeutics at The Children’s Hospital of Philadelphia